SELECT B — Selectimmune Pharma AB Share Price
Last trade - 00:00- SEK41.38m
- SEK35.54m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.15 | ||
| Price to Tang. Book | 7.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -141.9% | ||
| Return on Equity | -82.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Selectimmune Pharma AB is a Sweden-based pharmaceutical company. The Company develops new ways of equipping the host immune system to fight off the infections. The products are aimed at strengthening the immune system and are mainly used for the treatment of infectious diseases, as well as chronic inflammation. The Company is committed to exploring new medical innovations and solutions for the treatment of acute and chronic infections and their sequels. Selectimmune Pharma develops immunotherapies as alternatives to antibiotics.
Directors
- Last Annual
- June 30th, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 1st, 2017
- Public Since
- June 26th, 2019
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 17,459,225
- Address
- Klinikgatan 32, Lund, 222 42
- Web
- http://www.selectimmune.com/
- Phone
- Auditors
- Ernst & Young AB
Similar to SELECT B
Cessatech A/S
AktieTorget Stock Exchange
CS Medica A/S
AktieTorget Stock Exchange
Dicot AB
AktieTorget Stock Exchange
Odi Pharma AB (publ)
AktieTorget Stock Exchange
FAQ
As of Today at 01:20 UTC, shares in Selectimmune Pharma AB are trading at SEK2.50. This share price information is delayed by 15 minutes.
Shares in Selectimmune Pharma AB last closed at SEK2.50 and the price had moved by -46.47% over the past 365 days. In terms of relative price strength the Selectimmune Pharma AB share price has underperformed the FTSE Global All Cap Index by -50.95% over the past year.
There is no consensus recommendation for this security.
Selectimmune Pharma AB does not currently pay a dividend.
Selectimmune Pharma AB does not currently pay a dividend.
Selectimmune Pharma AB does not currently pay a dividend.
To buy shares in Selectimmune Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.50, shares in Selectimmune Pharma AB had a market capitalisation of SEK43.65m.
Here are the trading details for Selectimmune Pharma AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: SELECT B
Based on an overall assessment of its quality, value and momentum Selectimmune Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Selectimmune Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -20.66%.
As of the last closing price of SEK2.50, shares in Selectimmune Pharma AB were trading -10.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Selectimmune Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Selectimmune Pharma AB's directors